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Abstract. Autophagy, a process for catabolizing cytoplasmic compo-
nents, has been implicated in the modulation of interactions between
RNA viruses and their host. However, the mechanism underlying the
functional role of autophagy in the viral life cycle still remains
unclear. Hepatitis C virus (HCV) is a single-stranded, positive-sense,
membrane-enveloped RNA virus that can cause chronic liver disease.
Here we report that HCV induces the unfolded protein response
(UPR), which in turn activates the autophagic pathway to promote
HCV RNA replication in human hepatoma cells. Further analysis
revealed that the entire autophagic process through to complete
autolysosome maturation was required to promote HCV RNA replica-
tion and that it did so by suppressing innate antiviral immunity.
Gene silencing or activation of the UPR-autophagy pathway acti-
vated or repressed, respectively, IFN-b activation mediated by an
HCV-derived pathogen-associated molecular pattern (PAMP). Similar
results were achieved with a PAMP derived from Dengue virus (DEV),
indicating that HCV and DEV may both exploit the UPR-autophagy
pathway to escape the innate immune response. Taken together,
these results not only deﬁne the physiological signiﬁcance of
HCV-induced autophagy, but also shed light on the knowledge of
host cellular responses upon HCV infection as well as on exploration
of therapeutic targets for controlling HCV infection.
 2011 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.
The treatment of chronic hepatitis C, based on the combination of
Pegylated Interferon plus ribavirin, is only associated to approx-Journal of Hepatology 20
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[1]. Therefore, it is highly important to understand the molecular
interactions of the virus with the cell.
Autophagy regulates degradation of cytoplasmic components
such as proteins and organelles. This process contrasts with the
ubiquitin proteasome degradation pathway which speciﬁcally
recognizes ubiquitinated proteins for proteasomal degradation.
Autophagy is a multistep mechanism initiated by the formation
and the assembly of an isolated membrane, called the phago-
phore, around a portion of cytoplasm. The membrane extends
to form a closed autophagosome that then fuses with a lysosome
to form the autolysosome (or autophagolysosome) [2]. The inner
membrane and cytoplasmic components are captured and
degraded by lysosomal activities. More than 31 autophagy
related genes (ATG), whose products regulate the different steps
of autophagy, have been identiﬁed. The most typical trigger of
autophagy is nutrient starvation. Lack of any type of essential
nutrient such as amino acid, nitrogen or carbon can induce
autophagy. Moreover, autophagy regulates the constitutive turn-
over of cytosolic organelles critical for cell survival [2].
The unfolded protein response (UPR) detects cellular mis-
folded and unfolded proteins and targets its degradation by the
autophagy machinery. Newly synthesized and secretory proteins
are correctly folded and assembled in the endoplasmic reticulum
(ER). During a cellular stress, the ER loses its capacity to correct
protein folding, leading to the accumulation of unfolded proteins.
In response to ER stress, the UPR targets the degradation of the
proteins accumulated in the ER and activates the transcription
of genes encoding chaperones, lectins, and calcium pump activi-
ties that serve to increase the ER’s protein folding capacity [3].
Many studies demonstrated that autophagy is activated dur-
ing viral and bacterial infections. Autophagy has an antimicrobial
role by restricting intracellular microbial replication and/or by
maintaining the viability of infected cells. Many viruses have
evolved to counteract autophagy antiviral activity [4]. Indeed,
mouse hepatitis virus, poliovirus, dengue virus, and coxsackie
virus use elements of the autophagy machinery as membrane
scaffold to allow their own replication [4]. Different studies
described a critical role for autophagy during HCV infection [5–
11]. Using Huh 7.5 HCV infected cells, Sir et al. reported that
HCV induces autophagic vacuoles and an incomplete autophagy
to allow its replication [7]. Interestingly, using Huh 7 HCV
infected cells, Dreux et al. showed that autophagy is only required
for initiation of the HCV incoming replication and not to maintain


















Fig. 1. Interaction of HCV with the UPR-autophagy machinery. Autophagy
regulates degradation of cytoplasmic components. It is a multistep mechanism
initiated by the formation and assembly of a phagophore derivated from cellular
membrane. The phagophore then extends to form a closed autophagosome that
will fuse with a lysosome. The degradation is ensured by lysosomal activities.
Both UPR and autophagy are activated upon HCV infection [14]. Moreover, ER
stress is activated in vivo in patients with chronic hepatitis C [16]. Cyclophilin
inhibitors restrict (i) HCV replication [22–24] and (ii) autophagy activity [21].
Pathogen-associated molecular pattern (PAMP) recognition activates RIG-I and
leads to the production of interferon b. Autophagy inhibits PAMP-mediated IFNb
production in HCV infected cells [14].
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the replicons H77, Con1, and JFH1, down regulation of Atg pro-
teins does not modify viral proteins expression [6]. Interestingly,
another study showed that knocking down Atg7 drastically
reduces production of HCV particles while it does not modify
the expression of both viral RNA and proteins in infected cells
[9]. Furthermore, a recent report showed that the knock-down
of either autophagy related protein 1 (BCN1) or Atg7 inhibited
HCV replication in immortalized cells (IHHs) [11].
Moreover, the Atg5–Atg12 conjugate, a major component of
the autophagic machinery, has been shown to directly associate
with RIG-I, MDA5, and MAVS via their Cards domain [12]. These
interactions result in the inhibition of IFNb production. HCV
counteracts the antiviral activity of IFN signaling. Indeed, the core
protein activates SOCS3, resulting in the inhibition of Jak/STAT
signaling, and the viral protease NS3/4A induces MAVS proteo-
lytic cleavage to limit the production of IFNb [13].
The recent study by Ke and Chen [14] highlights the impor-
tance of the complete UPR autophagy machinery during HCV
infection. For the ﬁrst time, the authors elegantly described that
autophagy positively regulates HCV replication through its inhib-
itory activity on innate immunity. Ke et al. demonstrated that
HCV induces the autophagy machinery through activation of
the UPR machinery. Complete autophagy is needed for HCV
RNA replication. In Huh7 HCVcc infected cells, knocking down
members of the UPR-autophagy machinery (Atg5, CHOP, Ire1a,
ATF6, and Perk) induced reduction of intracellular HCV RNA lev-
els. Moreover, the addition of drugs inhibiting lysosome acidiﬁ-
cation, such as chloroquine, reduced the expression of NS5A
protein in Huh7 HCVcc infected cells. Interestingly, the activation
of IFNb promoter by RIG-I was increased in Huh7 HCVcc infected
cells with incomplete autophagy (either knocked down for Atg5
and CHOP).
Pathogen-associated molecular patterns (PAMPs) are small
molecules of RNA produced from viral genome during infec-
tion. PAMPs recognition activates RIG-I and stimulates the cel-
lular cascade leading to the production of IFNa/b. The authors
used viral PAMPs to assess whether autophagy can modulate
IFNb stimulation through regulation of PAMPs signaling. HCVcc
infected cells stimulated by HCV PAMPs showed a reduction in
IFNb production. The authors described that induction of IFNb
through HCV PAMPs was also occurring in uninfected cells
and that autophagy regulated PAMPs mediated IFNb production
in both non-infected and HCV infected cells. Altogether, these
results showed that autophagy negatively regulates IFNb
through viral PAMPs stimulation, and thus promotes HCV rep-
lication [14] (Fig. 1).
Several studies reported conﬂicting results about the impor-
tance of autophagy during HCV infection. However, these varia-
tions may be due to different experimental procedures. The use
of Huh 7.5 cells, for example, might modify the observation on
IFNb activation. Indeed, whereas Huh 7.5 cells are very permis-
sive to HCV infection, these cells harbor a defective mutation in
the RIG-I gene locus which may alter IFNb signaling pathway.
Moreover, using IHHs, Shrivastava et al. demonstrated as well
that autophagy regulates immune response in HCV infected
hepatocytes [11]. Infection at high multiplicity of infection
(MOI) may likely activate autophagy to limit the cytopathic effect
of such infection. Interestingly, Ke et al. demonstrated that even
at a low MOI (0.01) autophagy is activated upon HCV infection.
Moreover, the authors demonstrated that HCV-induced autoph-
agy coordinates with the infection stage.Journal of Hepatology 2011Interestingly, Cheng et al. showed that treatment with a pro-
tease inhibitor (BILN2061) does not restore ds-RNA-induced IFNb
promoter activity in HCV infected cells [15]. These results suggest
the existence of another signaling, NS3/4A independent, that may
modulate IFN pathway. Ke et al. suggested that activation of
autophagy might explain these observations. Moreover, Dreux
et al. reported that autophagy is required only for replication of
incoming viruses and not in an established infection [6]. At the
beginning of the infection whereas NS3/4A is not present at avol. 55 j 1150–1153 1151
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sufﬁcient level, autophagy might be activated to limit IFNb pro-
duction. Conversely, when the infection is established, the
expression of NS3/4A might be high enough to regulate IFNb pro-
duction and it might explain why Dreux et al. did not report an
effect of autophagy in an established infection.
It is likely that HCV is using autophagy to promote its replica-
tion because autophagy primarily has an antiviral activity. HCV
might encode an activity able to regulate the UPR-autophagy
machinery. Ke et al. results suggest that HCV RNA replication is
the mechanism that induces UPR and autophagy.
In vivo, few studies investigated the role of autophagy during
HCV infection. We previously described an activation of the ER
stress and UPR sensors in liver biopsies of HCV infected patients
[16]. Whereas ER stress related genes showed higher expression
in HCV patients, UPR related genes were not signiﬁcantly up-reg-
ulated [16]. In this study, the autophagy activity was not investi-
gated in vivo. The absence of UPR genes up-regulation is not
necessarily associated with normal activity of UPR and autoph-
agy. Autophagy activation in vivo might be induced by hepato-
cytes ER stress. Ke et al. knocked down either the UPR or
autophagy components [14]. Since, upstream, ER stress is able
to activate UPR, it would be interesting to investigate if knocking
down a component of ER stress would have the same effect on
IFNb activation than knocking down UPR and autophagy
components.
A recent study performed in our group showed an increased
autophagic response in patients with chronic hepatitis C in com-
parison with patients with no or mild ﬁbrosis, NASH, and chronic
hepatitis B [17]. Moreover, autophagic vesicles accumulate in
hepatocytes independently of the HCV genotype. Although elec-
tron microscopy showed a strong accumulation of autophago-
some vesicles, mature lysosomes do not increase in
hepatocytes. These observations are in accordance with previous
in vitro studies reporting an incomplete autophagy in HCV
infected cells [7].
Interestingly, two independent studies reported that IFNb
production is increased in HCV infected cells harboring incom-
plete autophagy [11,14]. Thus, in response to IFNb stimulation,
interferon stimulated genes (ISGs) might be up-regulated in
infected and neighbor cells. This is a very interesting ﬁnding since
anti HCV therapy is based on the combination of PEG-IFNa plus
ribavirin. Moreover, several reports showed that a high level of
expression of ISGs before the treatment is associated with non
response [18–20]. These observations raise the hypothesis that
autophagy might be down-regulated in non responders, resulting
in an increased expression of ISGs.
Cyclophilins are molecular chaperons encoding a peptidyl-
prolyl cis–trans isomerase activity. As chaperons, cyclophilins tar-
get misfolded proteins to the UPR autophagy machinery. Interest-
ingly, it has been reported that the addition of an inhibitor of
cyclophilins, cyclosporin A, reduced the activity of autophagy
induced by nutrient starvation [21]. Moreover, several reports
demonstrated that cyclophilins are required for HCV replication
[9,22–24]. In vitro, cyclosporine A shows a potent antiviral effect
against HCV replication. Debio 025 is an inhibitor of Cyps that
derivates from cyclosporine A and does not display calcineurin
inhibition. A phase II study in treatment-naïve patients with
chronic hepatitis C conﬁrmed that Debio 025 has a potent activity
[25]. Since cyclosporine A reduces autophagy in vitro, Debio 025
might also restrict autophagy activity in patients. Ke et al.
reported that inhibition of autophagy increases the production1152 Journal of Hepatology 2011of IFNb [14]. Altogether, these results suggest that cyclophilin
inhibitors may restrict HCV replication and innate immune
response through inhibition of autophagy.
Interestingly, Ke et al. described a new role of autophagy in
the regulation of innate immunity during HCV infection [14].
HCV may encode an NS3/4A independent activity that triggers
autophagy to limit the production of IFNb.
Cyclophilin inhibitors might act as a potent anti-autophagy
agent and limit both inhibition of innate antiviral response and
HCV replication.Conﬂict of interest
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